Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astrazeneca Plc (AZN)
NASDAQ:AZN
Holding AZN?
Track your performance easily
AZN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$60.47 - $87.68
Previous Close$65.35
Volume9.08M
Average Volume (3M)5.62M
Market Cap
$199.81B
Enterprise Value$222.61B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)31.2
Beta0.35
Next Earnings
Feb 06, 2025EPS Estimate
$1.06Last Dividend Ex-Date
Aug 09, 2024Dividend Yield2.23%
Share Statistics
EPS (TTM)2.10
Shares Outstanding3,100,634,378
10 Day Avg. Volume5,171,923
30 Day Avg. Volume5,624,811
Standard Deviation0.06
R-Squared0.15
Alpha0.00382
Financial Highlights & Ratios
Price to Book (P/B)2.56
Price to Sales (P/S)4.34
Price to Cash Flow (P/CF)19.10
P/FCF Ratio26.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.02
Enterprise Value/Gross Profit5.93
Enterprise Value/Ebitda24.51
Forecast
1Y Price Target
$89.50Price Target Upside36.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
AstraZeneca News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAstraZeneca reported total revenues of $13.565 billion, beating consensus by 4%.
Guidance And OutlookAstraZeneca raised its 2024 guidance, expecting higher growth in total revenue and core EPS.
Pipeline And CatalystsStrong fundamentals such as low IP risks, active label expansion, and a diverse pipeline with near-term catalysts suggest AZN's value is not fully reflected in its share price.
Bears Say
Legal And Regulatory IssuesCurrent and past AstraZeneca employees are being investigated for illegal drug importation into China and inappropriate collection of patient data.
Product DevelopmentRoche discontinued development of ipatasertib during their update after disappointing results in trials for TNBC and HR+/HER2- and PTEN-mutated breast cancer.
Regulatory ChallengesThe withdrawal of their BLA submission for datopotamab deruxtecan for non-squamous non-small cell lung cancer led to a lower target price.
---
Ownership Overview
―
Insiders
6.17% Mutual Funds
6.24% Other Institutional Investors
86.75% Public Companies and Individual Investors
AZN FAQ
What was Astrazeneca Plc’s price range in the past 12 months?
Astrazeneca Plc lowest stock price was $60.47 and its highest was $87.67 in the past 12 months.
What is Astrazeneca Plc’s market cap?
Currently, no data Available
When is Astrazeneca Plc’s upcoming earnings report date?
Astrazeneca Plc’s upcoming earnings report date is Feb 06, 2025 which is in 46 days.
How were Astrazeneca Plc’s earnings last quarter?
Astrazeneca Plc released its earnings results on Nov 12, 2024. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.021 by $0.019.
Is Astrazeneca Plc overvalued?
According to Wall Street analysts Astrazeneca Plc’s price is currently Undervalued.
Does Astrazeneca Plc pay dividends?
Astrazeneca Plc pays a Semiannually dividend of $0.49 which represents an annual dividend yield of 2.23%. See more information on Astrazeneca Plc dividends here
What is Astrazeneca Plc’s EPS estimate?
Astrazeneca Plc’s EPS estimate is $1.06.
How many shares outstanding does Astrazeneca Plc have?
Astrazeneca Plc has 3,100,634,300 shares outstanding.
What happened to Astrazeneca Plc’s price movement after its last earnings report?
Astrazeneca Plc reported an EPS of $1.04 in its last earnings report, beating expectations of $1.021. Following the earnings report the stock price went up 0.617%.
Which hedge fund is a major shareholder of Astrazeneca Plc?
Among the largest hedge funds holding Astrazeneca Plc’s share is PRIMECAP Management Co. It holds Astrazeneca Plc’s shares valued at 3B.
---
AstraZeneca Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.50 (36.95% Upside)
$89.50 (36.95% Upside)
Blogger Sentiment
Bullish
AZN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.44%
12-Months-Change
Fundamentals
Return on Equity
16.67%
Trailing 12-Months
Asset Growth
9.20%
Trailing 12-Months
Company Description
Astrazeneca Plc
Founded in 1992, UK-based AstraZeneca Plc is a leading global pharmaceutical company, which is engaged in delivering life-changing medicines. The company produces and commercializes medicines for cancer, gastrointestinal, cardiovascular, neuroscience, oncology, respiratory and inflammation and other infectious diseases.
---
AZN Company Deck
---
AZN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with significant revenue growth across regions and sectors, an upgraded full-year guidance, and promising pipeline developments. However, uncertainties in China due to ongoing investigations, potential impacts from Farxiga's VBP inclusion, and IRA headwinds pose challenges. Despite these concerns, the overall sentiment remains optimistic with strategic investments and a robust R&D pipeline.Read More>---
AZN Stock 12 Month Forecast
Average Price Target
$89.50
▲(36.95% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
23/33 ratings generated profit
1 Year Average Return
+7.62%
reiterated a buy rating 27 days ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 69.70% of your transactions generating a profit, with an average return of +7.62% per trade.
---